tbuckley/cabot-search huggingface dataset:
Ludwig's angina
Authors: R. G. Finch
Journal: JAMA (1980)

LUDWIG'S angina is a life-threatening infection of the sublingual and submandibular spaces, first described by Von Ludwig in 1836. Before the widespread use of antibiotics, the disease seems to have occurred relatively frequently, as evidenced by several large series.<sup>1,2</sup>In recent years, scattered case reports make up most of the available information,<sup>3,4</sup>suggesting that the disease is now either less commonly seen or recognized. Mortality has exceeded 50%,<sup>2</sup>and fatalities are still reported.<sup>5</sup>Our recent experience with six cases of Ludwig's angina seen over a 32-month period has prompted this review. Despite the critical nature of their illness, all of our patients showed a prompt and complete response to treatment. Table 1 summarizes some clinical features present on admission, while Table 2 outlines the roentgenographic, surgical, and antibiotic aspects of the management of these six cases. <h3>Pathogenesis</h3> Ludwig's angina may arise de novo, but this is
Massachusetts Medical Society
Authors: Eliot Hubbard
Journal: New England Journal of Medicine (1957)

PLACEMENT SERVICEAfter World War II, one of the many problems confronting the medical field was that of the reestablishment in private practice of physicians who had served in the armed forces.The president of the American Medical Association, realizing the need for some kind of organization that could collect information on available openings for physicians from private and governmental agencies, appealed to the House of Delegates at the Annual Session in June, 1944, "for authority to establish a Bureau of Information in the American Medical Association Headquarters."The Bureau of Information later became the Placement Bureau of the American . . .
Dyslipidemia is a risk factor for aortic atherosclerosis: A population-based transesophageal echocardiographic study Yoram Agmon, Bijoy K. Khandheria, Irene Meissner, Tanya M. Petterson, W. M. O'Fallon, David O. Wiebers, A. J. Tajik, James B. Seward. Mayo Clinic and Mayo Foundation, Rochester, MN
Journal: Journal of the American College of Cardiology (2001)
In Reply
Authors: Jean-Pascal Machiels
Journal: Journal of Clinical Oncology (2009)

a chemotherapy arm and the same chemotherapy plus estramustine were obtained in a recently reported meta-analysis. 7Results significantly favored the chemotherapy plus estramustine arm in terms of PSA response rate (P Ͻ .0001),progression-free survival (hazard ratio [HR]: 0.74; P Ͻ .01),and overall survival (HR: 0.77; P Ͻ .008).More than 20 years after its approval for the treatment of patients with CRPC, whether the antitumor activity of estramustine is mostly related to its hormonal or cytotoxic effects is still largely unknown.A number of recent data indicate that CRPC is often still an androgen receptor-driven disease. 8The activity detected in the clinic with hormone-modulating agents like ketoconazole, diethylstilbestrol, and more recently, abiraterone acetate, act in a similar way, and the benefit of adding estramustine to chemotherapy over chemotherapy alone could well be explained by such an endocrine effect.Ideally, a large, well-designed phase III randomized trial would be required to properly answer this question.However, it is not certain that such a trial will be done in the future since other trial priorities exist, and estramustine, as a mature drug, has become an orphan drug with less support from the pharmaceutical industry.
<i>QuickStats</i>: Percentage* of All Visits by Patients Aged ≥65 Years to Office-Based Physicians† Made by Patients with Hypertension,§ by Sex and Metropolitan Statistical Area (MSA)¶ — National Ambulatory Medical Care Survey, United States, 2012–2015
Journal: MMWR Morbidity and Mortality Weekly Report (2017)

During 2012-2015, patients aged ≥65 years with hypertension documented in the medical record accounted for 54% of all office-based physician visits made by patients aged ≥65 years, with a higher percentage of visits in non-MSAs (59%) than MSAs (53%). Among women, the percentage of visits was also higher in non-MSAs than in MSAs (59% versus 53%). The difference among men was not statistically significant.
What's new in the other general journals
Authors: Kristina Fister
Journal: BMJ (2006)

The aetiology of Parkinson's disease is largely unknown, but genetic factors may be implicated. The most promising association of a gene with susceptibility for Parkinson's disease seems to be that of the α-synuclein gene, but previous studies gave conflicting results. Credit: JAMA A collaboration of 18 teams of researchers worldwide analysed published and unpublished individual data for more than 5000 people. They found that variability in the length of a dinucleotide repeat sequence (REP1) in the promoter of the α-synuclein gene was associated with susceptibility to Parkinson's disease: the 263 base pair allele conveyed an increased risk of developing the disease, whereas the 259 base pair allele seemed to be protective. However, the gene variants did not seem to modify the age of disease onset. Credit: N ENGL J MED The gene codes for the α-synuclein protein, which is abnormally aggregated in the neurones of people with Parkinson's disease, although only about 1% of people with the disease have a mutated α-synuclein gene. The α-synuclein protein is also the major compound of Lewy bodies, the pathohistological marker of Parkinson's disease. If overexpression of the α-synuclein gene was a common underlying pathophysiological mechanism in people with the disease, this would offer opportunities for new drugs targeted at reducing expression of the gene. As yet, however, there is no robust evidence for this. Large longitudinal studies are needed to assess whether the gene has a modifying effect on the course of the disease. JAMA2006; 296: 661–70 [OpenUrl][1][CrossRef][2][PubMed][3][Web of Science][4] Concerns raised over the ability of people infected with HIV in sub-Saharan Africa to adhere to antiretroviral treatment seem to contribute to delayed access to treatment. A recent meta-analysis showed that these concerns are unjustified. A comprehensive search for available data on adherence rates found 31 studies (17 573 patients) from North America and 27 studies (12 116 patients) … [1]: {openurl}?query=rft.jtitle%253DJAMA%26rft.stitle%253DJAMA%26rft.issn%253D0002-9955%26rft.aulast%253DMaraganore%26rft.auinit1%253DD.%2BM.%26rft.volume%253D296%26rft.issue%253D6%26rft.spage%253D661%26rft.epage%253D670%26rft.atitle%253DCollaborative%2Banalysis%2Bof%2Balpha-synuclein%2Bgene%2Bpromoter%2Bvariability%2Band%2BParkinson%2Bdisease.%26rft_id%253Dinfo%253Adoi%252F10.1001%252Fjama.296.6.661%26rft_id%253Dinfo%253Apmid%252F16896109%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx [2]: /lookup/external-ref?access_num=10.1001/jama.296.6.661&link_type=DOI [3]: /lookup/external-ref?access_num=16896109&link_type=MED&atom=%2Fbmj%2F333%2F7564%2F387.atom [4]: /lookup/external-ref?access_num=000239603800028&link_type=ISI
Endocrinology
Journal: JAMA (1998)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Dabrafenib Active in Rare NSCLC Subtype
Journal: Cancer Discovery (2016)

Results from a phase II trial show that the BRAF inhibitor dabrafenib has significant single-agent activity in patients with advanced non-small cell lung cancer harboring the BRAF V600E mutation. However, data from another arm of the study suggest that combining dabrafenib with a MEK inhibitor may be a more effective treatment strategy for these patients.
Deaths
Journal: JAMA (1934)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Human herpesvirus type 8 is not associated with pyogenic granulomas with satellite recurrence
Authors: G. De Aloe, P. Rubegni, L. Pacenti, C. Miracco, M. Fimiani
Journal: British Journal of Dermatology (2001)

Journal Article Human herpesvirus type 8 is not associated with pyogenic granulomas with satellite recurrence Get access G. De Aloe, G. De Aloe Istituto di Scienze Dermatologiche and Search for other works by this author on: Oxford Academic Google Scholar P. Rubegni, P. Rubegni Istituto di Scienze Dermatologiche and Search for other works by this author on: Oxford Academic Google Scholar L. Pacenti, L. Pacenti Istituto di Anatomia Patologica, Università degli Studi di Siena, Viale Bracci 53100, Siena, Italy Correspondence: Pietro Rubegni.E‐mail: rubegni@unisi.it Search for other works by this author on: Oxford Academic Google Scholar C. Miracco, C. Miracco Istituto di Anatomia Patologica, Università degli Studi di Siena, Viale Bracci 53100, Siena, Italy Correspondence: Pietro Rubegni.E‐mail: rubegni@unisi.it Search for other works by this author on: Oxford Academic Google Scholar M. Fimiani M. Fimiani Istituto di Scienze Dermatologiche and Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 144, Issue 1, 1 January 2001, Pages 202–203, https://doi.org/10.1111/j.1365-2133.2001.03986.x Published: 01 January 2001
Serum cholesterol levels and cancer mortality in 361,662 men screened for the Multiple Risk Factor Intervention Trial
Authors: R. W. Sherwin
Journal: JAMA (1987)

Several prospective studies have demonstrated an association between low serum cholesterol level and subsequent mortality from cancer. This finding was explored in the large cohort (361 662) of men aged 35 to 57 years who were screened for possible randomization to the Multiple Risk Factor Intervention Trial. Mortality follow-up revealed a significant excess of cancer in the lowest decile of serum cholesterol level during the early years of follow-up, which attenuated over time. In contrast, the association between high serum cholesterol and coronary heart disease did not diminish during the average of seven years of follow-up. These findings are consistent with the inference that the association between low serum cholesterol level and cancer is at least in part due to an effect of preclinical cancer on serum cholesterol level. A subset of the cohort (12866 men) participated in the randomized Multiple Risk Factor Intervention Trial protocol, which called for annual measurements of serum cholesterol level. Among the 150 of these men who died of cancer during the trial, cholesterol level fell 22.7 mg/dL (0.59 mmol/L) more than in the survivors over an equivalent period. These data are consistent with the foregoing inference. (<i>JAMA</i>1987;257:943-948)
A Welcome
Authors: TRUMAN G. SCHNABEL
Journal: Annals of Internal Medicine (1962)

Editorials1 March 1962A WelcomeTRUMAN G. SCHNABEL JR., M.D., F.A.C.P.TRUMAN G. SCHNABEL JR., M.D., F.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-56-3-526 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptPhiladelphia welcomes you. There is no doubt about that. Philadelphia's welcomes have been warm ever since William Penn, with Quaker fair-mindedness, knew how to make even the Indians feel welcome on their own land. Doctors have always been especially welcomed by Benjamin Franklin's ingenious scientific city—the city of yellow fever and Dr. Rush; of Dr. Physick, whose house is still here; of Morgan and Shippen and Osler; of Gross, Weir Mitchell, and Agnew; of Deaver, the Peppers, and A. N. Richards. Five medical schools are glad you are visiting us—Hahnemann, Jefferson, Temple, Woman's, and the University of Pennsylvania. Doctors can... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: American College of Physicians Philadelphia, Pennsylvania PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 March 1962Volume 56, Issue 3Page: 526-527KeywordsFevers ePublished: 1 December 2008 Issue Published: 1 March 1962 PDF downloadLoading ...
Incorrect Value in Abstract in: Benefits and Harms of CT Screening for Lung Cancer: a Systematic Review
Journal: JAMA (2013)

Peter B. Bach, MD, MAPP; Joshua N. Mirkin, BA; Thomas K. Oliver, BA; Christopher G. Azzoli, MD; Donald A. Berry, PhD; Otis W. Brawley, MD; Tim Byers, MD, MPH; Graham A. Colditz, MD, DrPH; Michael K. Gould, MD, MS; James R. Jett, MD; Anita L. Sabichi, MD; Rebecca Smith-Bindman, MD; Douglas E. Wood, MD; Amir Qaseem, MD, PhD, MHA; Frank C. Detterbeck, MD
Intramural hemorrhage of the small intestine
Authors: M. Eiland
Journal: JAMA (1978)

IN 1954, Felson and Levin<sup>1</sup>described certain roentgenographic findings that were considered characteristic of intramural hemorrhage in the gastrointestinal tract. Since then others have described additional typical findings and have suggested pathophysiological processes to account for them. Although there is some disagreement as to how specific the diagnosis can be, there is agreement on the general appearance of intramural hemorrhage on plain films and barium contrast studies. With increasing awareness of this entity has come an increase in the number of pathological conditions shown to predispose to intramural hemorrhage. These conditions include trauma, anticoagulation therapy, hemophilia, Henoch-Schönlein purpura, idiopathic thrombocytopenic purpura, leukemia, lymphoma, cytotoxic therapy for neoplasm, polyarteritis nodosa, and myeloma. We will discuss the roentgenographic features of intramural hemorrhage, its course, and its mode of management, and will present illustrative cases. <h3>Report of Cases</h3><h3>Case 1.—</h3> An 80-year-old woman was admitted to the hospital with a three-day history
Guidelines in the management of the exercising patient
Authors: K. H. Cooper
Journal: JAMA (1970)

The current widespread interest in jogging and the frequency of ischemic heart disease in the American male population have prompted many physicians to request specific guidelines in the management of patients who wish to begin an exercise program. This communication provides such guidelines in the following areas: The type and the importance of the initial medical examination; physical fitness testing, its value and its risks; contraindications and abnormal responses to exercise; and restrictions to be placed upon the older exercising patient. With this information, physicians can better advise their patients about the hazards associated with exercise as well as the use of exercise as a therapeutic tool.
Heterogeneity in chemoresponsiveness of ovarian cancer as demonstrated by an ex vivo chemo response assay
Authors: R. Ochs, H. Gallion, R. Coleman, T. Herzog, B.-U. Sevin, H. Schellhas, A. Wells
Journal: Journal of Clinical Oncology (2004)

5059 Background: Only a subset of patients responds to a given chemotherapeutic regimen. The purpose of this analysis was to determine whether tumors are generally sensitive or resistant regardless of regimen, or do they demonstrate heterogeneity in responsiveness across regimens. Methods: We examined the ex vivo chemoresponse of ovarian cancer cells from 256 women across 9 practices. An average of 8 drug regimens, including combinations, were tested per tumor. The assay results were scored for sensitivity or resistance based on live cell number after exposure to varied concentrations of each chemotherapeutic regimen. Patients were classified into three groups: predominantly sensitive (>83% of regimens tested scored sensitive for their tumor), predominantly resistant (>83% tested resistant), and heterogeneous. Results: 51 of 256 (20%) cases were predominantly sensitive, with a median progression free interval (PFI) of 17.7 months. 34 (13%) cases were predominantly resistant, with a median PFI of 9.9 months. Two thirds of cases (N=171) exhibited heterogeneity of response, with a median PFI of 11.4 months. Within the heterogeneous group, those who received a regimen scored as sensitive ex-vivo (no other regimens tested were scored more sensitive than the regimen they received) vs resistant ex-vivo had an improved median PFI: 12.4 months (N=46) vs 8.6 months (N=125). Conclusions: The majority of tumors tested demonstrated heterogeneity of response ex vivo. As heterogeneity of chemotherapy response for an individual patient cannot be assessed clinically, an ex vivo assay assessment is informative. Moreover, our data suggests that individualizing therapy by incorporating an ex vivo assay has the potential to increase the response rates to chemotherapy. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Precision Therapeutics, Inc. Precision Therapeutics, Inc. Precision Therapeutics, Inc.
An Account of Twelve Months of Health Defense Containing the Activities of the Health Department of the City of New York for 1940 with Comparative Vital Statistics Tables and a Review of Developments Since 1934
Journal: JAMA (1942)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The effect of preexisting conditions on mortality in trauma patients
Authors: J. A. Morris
Journal: JAMA (1990)

A case-control design was used to investigate the effects of preexisting chronic conditions on in-hospital mortality in adult trauma patients. Cases consisted of all trauma deaths (n = 3074) that occurred in 1983 in any of the 331 acute care hospitals in California. Three to four control patients (injured survivors) were matched to each case patient on the basis of injury severity, age, and individual hospital (n = 9869). The data source consisted of hospital discharge abstract data uniformly collected on all admissions to acute care hospitals in the state. Conditional logistic regression techniques were used to estimate the relative odds of dying for patients with and without one or more of 11 preexisting chronic conditions identified as potentially detrimental to outcome. The presence of cirrhosis (relative odds = 4.5), congenital coagulopathy (relative odds = 3.2), ischemic heart disease (relative odds = 1.8), chronic obstructive pulmonary disease (relative odds = 1.8), and diabetes (relative odds = 1.2) all significantly increased the risk of dying. These data provide statistical evidence to support the recommendation of the American College of Surgeons that the presence of underlying disease be considered in decisions to triage and transfer patients to trauma centers. They also underscore the importance of underlying disease in the case-mix adjustment of case-fatality rates and the identification of unexpected deaths for quality assurance review. (<i>JAMA</i>. 1990;263:1942-1946)
Editorial: "Keep your cool".
Journal: BMJ (1974)

at any rate25).It inhibits membrane bound ATP-ase at a much lower concentration than other divalent ions such as lead and mercury, and it may also labilize the lysosomes.A 0.1% aerosol of cadmium chloride can produce a centri- lobular emphysema-like lesion in rats.26The time scale of human emphysema makes it likely that the lesions result from repeated doses of inhaled pollutants, particularly those in cigarette smoke.One or more of these may activate the disease process in the centriacinar regions in the upper zones, while others, penetrating more deeply and widely, may cause lesions in the alveolar ducts and alveoli.It seems probable, then, that the initial damage to the respiratory bronchioles in centriacinar emphysema is dif- ferent from that to the alveolar duct region in the panacinar type.Nevertheless these lesions could be caused by the same pollutant acting at different sites, or by different pollutants, perhaps in the same tobacco smoke.Which of these possi- bilities would constitute two diseases is academic in the face of our continuing inability to recognize emphysema in life at all until it is far advanced, or actively to halt or reverse it.